Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial.

ABSTRACT:

Background

The risk of death from prostate cancer (PC) depends on age, but the age at which to start prostate-specific antigen (PSA) screening remains uncertain.

Objective

To study the relationship between risk reduction for PC mortality and age at first PSA screening.

Design, setting, and participants

The randomized Göteborg-1 trial invited men for biennial PSA screening between the ages of 50 and 70 yr (screening, n = 10 000) or no invitation but exposure to opportunistic PSA testing (control, n = 10 000).

Intervention

Regular versus opportunistic PSA screening or no PSA.

Outcome measurements and statistical analysis

We modeled the nonlinear association between starting age and the absolute risk reduction in PC mortality in three settings: (1) intentio

SUBMITTER: Carlsson SV 

PROVIDER: S-EPMC10481420 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature